Why Exact Sciences Stock Is Moving Higher After Hours
Portfolio Pulse from Adam Eckert
Exact Sciences Corp (NASDAQ:EXAS) announced positive top-line results from its BLUE-C study, showing that its Cologuard test demonstrated 94% sensitivity for colorectal cancer at 91% specificity. The company plans to release additional analyses and complete its FDA application for Cologuard approval in the coming months.
June 20, 2023 | 8:42 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Exact Sciences' Cologuard test demonstrated 94% sensitivity for colorectal cancer, and the company plans to complete its FDA application soon.
The positive top-line results from the BLUE-C study indicate that Exact Sciences' Cologuard test is highly effective in detecting colorectal cancer. This news is likely to boost investor confidence in the company's product and its potential for FDA approval, leading to a positive short-term impact on the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100